We are live on ! Find out more
BNTX icon

BioNTech

280 hedge funds and large institutions have $4.27B invested in BioNTech in 2023 Q4 according to their latest regulatory filings, with 60 funds opening new positions, 91 increasing their positions, 68 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more capital inflows, than outflows

Capital inflows: $669M | Capital outflows: $317M

54% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 39

34% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 68

12% more funds holding

Funds holding: 251 → 280 (+29)

1.65% more ownership

Funds ownership: 15.41% → 17.06% (+1.7%)

5% more call options, than puts

Call options by funds: $234M | Put options by funds: $224M

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
280
Holders Change
+29
Holders Change %
+11.55%
% of All Funds
4.07%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
60
Increased
91
Reduced
68
Closed
39
Calls
$234​M
Puts
$224​M
Net Calls
+$10.8​M
Net Calls Change
+$12.2​M

BNTX Hedge Fund Activity: Q4 2023 in Review

280 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q4 2023, worth a combined $4.27B — up 6.6% from $4.01B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new BNTX positions and 39 closed out — a net gain of 21 holders — while 91 added to existing stakes and 68 trimmed.

The largest buyer was Harding Loevner, opening a new position worth an estimated $397M. The largest seller was Artisan Partners, cutting an estimated $67.6M.

  • 280 institutional investors held BioNTech (BNTX) as of Q4 2023, up from 251 in Q3 2023.
  • Funds reported $4.27B of BioNTech stock for Q4 2023, up 6.6% quarter-over-quarter.
  • 60 funds opened new BioNTech positions in Q4 2023 and 39 closed out, a net change of +21 holders.
  • The largest BioNTech buyer in Q4 2023 was Harding Loevner, an estimated $397M added.
  • The largest BioNTech seller in Q4 2023 was Artisan Partners, an estimated $67.6M sold.

Based on aggregated 13F filings for Q4 2023.